参考文献/References:
[1] Joglar JA,Chung MK,Armbruster AL,et al.2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation,2024,149(1):e1-e156.
[2] January CT,Wann LS,Alpert JS ,et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [J]. J Am Coll Cardiol,2014,64(21):e1-e76.
[3] January CT,Wann LS,Calkins H,et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [J]. J Am Coll Cardiol,2019,74(1):104-132.
[4] Singer DE,Chang Y,Borowsky LH,et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation:the ATRIA study stroke risk score [J]. J Am Heart Assoc,2013,2(3):e000250.
[5] Lip GY,Nieuwlaat R,Pisters R,et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach:the euro heart survey on atrial fibrillation [J]. Chest,2010,137(2):263-272.
[6] Fox KAA,Lucas JE,Pieper KS,et al. Improved risk stratification of patients with atrial fibrillation:an integrated GARFIELD-AF tool for the prediction of mortality,stroke and bleed in patients with and without anticoagulation [J]. BMJ Open,2017,7(12):e017157.
[7]Kaplan RM,Koehler J,Ziegler PD,et al. Stroke risk as a function of atrial fibrillation duration and CHA2DS2-VASc score[J]. Circulation,2019,140(20):1639-1646.
[8] Reddy VY,Doshi SK,Kar S,et al. 5-Year outcomes after left atrial appendage closure:from the PREVAIL and PROTECT AF trials [J]. J Am Coll Cardiol,2017,70(24):2964-2975.
[9] Osmancik P,Herman D,Neuzil P,et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation [J]. J Am Coll Cardiol,2020,75(25):3122-3135.
[10] Reddy VY,Mobius-Winkler S,Miller MA,et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation:the ASAP study(ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology) [J]. J Am Coll Cardiol,2013,61(25):2551-2556.
[11] Kirchhof P,Camm AJ,Goette A,et al. Early rhythm-control therapy in patients with atrial fibrillation [J]. N Engl J Med,2020,383(14):1305-1316.
[12] Kim D,Yang PS,You SC,et al. Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation:nationwide cohort study [J]. BMJ,2021,373:n991.
[13] Dickow J,Kirchhof P, van Houten HK,et al. Generalizability of the EAST-AFNET 4 Trial:assessing outcomes of early rhythm-control therapy in patients with atrial fibrillation[J]. J Am Heart Assoc,2022,11(11):e024214.
[14] Chung MK,Eckhardt LL,Chen LY,et al. Lifestyle and risk factor modification for reduction of atrial fibrillation:a scientific statement from the American Heart Association [J]. Circulation,2020,141(16):e750-e772.
[15]Packer DL,Kowal RC,Wheelan KR,et al. Cryoballoon ablation of pulmonary
veins for paroxysmal atrial fibrillation:first results of the North American
Arctic Front(STOP AF) pivotal trial[J]. J Am Coll Cardiol,2013,61:1713-1723.
[16]Marrouche NF,Brachmann J,Andresen D,et al. Catheter ablation for atrial
fibrillation with heart failure[J]. N Engl J Med,2018,378:417-427.
[17]Packer DL,Piccini JP,Monahan KH,et al. Ablation versus drug therapy for
atrial fibrillation in heart failure:results from the CABANA trial[J]. Circulation,2021,143:1377-1390.
[18] Gopinathannair R,Chen LY,Chung MK,et al. Managing atrial fibrillation in patients with heart failure and reduced ejection fraction:a scientific statement from the American Heart Association [J]. Circ Arrhythm Electrophysiol,2021,14(6):HAE0000000000000078.
[19] Ari H,Gürdogan M,Erdogan E,et al. Short-term outcome of early electrical cardioversion for atrial fibrillation in hyperthyroid versus euthyroid patients [J]. Cardiol J,2012,19(1):53-60.
[20] Goldstein SA,Green J,Huber K,et al. Characteristics and outcomes of atrial fibrillation in patients with thyroid disease(from the ARISTOTLE trial)[J]. Am J Cardiol,2019,124(9):1406-1412.
[21] Razvi S,Jabbar A,Pingitore A,et al. Thyroid hormones and cardiovascular function and diseases[J]. J Am Coll Cardiol,2018,71(16):1781-1796.